- Home
- GOVX vs IMCC Comparison
GOVX vs IMCC Comparison
Compare GOVX & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOVX | IMCC |
|---|---|---|
| Founded | 2001 | 1980 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 10.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GOVX | IMCC |
|---|---|---|
| Price | $0.25 | $1.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 651.7K | 269.0K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,353,560.00 | ★ $37,606,703.00 |
| Revenue This Year | N/A | $47.12 |
| Revenue Next Year | N/A | $12.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.52 | 1.92 |
| 52 Week Low | $0.28 | $0.93 |
| 52 Week High | $2.75 | $7.12 |
Technical Indicators
Market Signals| Indicator | GOVX | IMCC |
|---|---|---|
| Relative Strength Index (RSI) | 22.60 | 54.00 |
| Support Level | $0.37 | $1.39 |
| Resistance Level | $0.41 | $2.08 |
| Average True Range (ATR) | 0.04 | 0.22 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 2.30 | 52.17 |
Price Performance
Historical ComparisonAbout GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.